Lipella Pharmaceuticals (LIPO) CEO issues letter following delisting Jun 25, 2025 03:15PM
Lipella Pharmaceuticals (LIPO) delisted from Nasdaq Jun 20, 2025 03:20PM
Lipella Pharmaceuticals (LIPO) Announces U.S. Patent Issuance for Diagnostic Technology Jun 17, 2025 08:31AM
Lipella Pharmaceuticals (LIPO) Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Jun 4, 2025 08:30AM
Lipella Pharmaceuticals (LIPO) Reports Positive Topline Phase 2a Results for LP-310 Feb 11, 2025 05:58AM


Feb 6, 2025 06:00AM Lipella Pharmaceuticals (LIPO) Granted FDA Approval for Expanded Access Program for LP-310
Nov 21, 2024 05:34AM Lipella Pharmaceuticals (LIPO) Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus
Nov 1, 2024 04:32PM Lipella Pharmaceuticals (LIPO) Announces 1:8 Reverse Share Split
Oct 15, 2024 06:07AM Lipella Pharmaceuticals (LIPO) Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
Sep 24, 2024 08:01AM Lipella Pharmaceuticals (LIPO) Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310
Aug 22, 2024 06:39AM Lipella Pharmaceuticals (LIPO) Launches Innovative Registry to Advance Oral Lichen Planus Research
Aug 12, 2024 05:01AM Lipella Pharmaceuticals (LIPO) Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
Aug 1, 2024 08:01AM Lipella Pharmaceuticals (LIPO) Announces 2.07M Share Offering at $0.62/sh
Jul 29, 2024 07:38AM Lipella Pharmaceuticals (LIPO) Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients